Trials / Terminated
TerminatedNCT00080132
Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy
An Open-Label, Dose-Escalating Efficacy and Safety Study of Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (planned)
- Sponsor
- Medical Research Laboratories International · Industry
- Sex
- All
- Age
- 8 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if implitapide is effective in lowering triglyceride (TG) levels in patients with Fredrickson Type I or V hypertriglyceridemia where the maximum tolerable medication and diet were not sufficient.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | implitapide |
Timeline
- Start date
- 2004-10-01
- Completion
- 2005-04-01
- First posted
- 2004-03-25
- Last updated
- 2005-06-24
Locations
9 sites across 3 countries: United States, Netherlands, Norway
Source: ClinicalTrials.gov record NCT00080132. Inclusion in this directory is not an endorsement.